Outlook Therapeutics Inc. [NASDAQ: OTLK] traded at a low on 01/29/21, posting a -23.35 loss after which it closed the day’ session at $0.94. The company report on January 29, 2021 that Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.00 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 2, 2021, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
The results of the trading session contributed to over 24251120 shares changing hands. Over the past one week, the price volatility of Outlook Therapeutics Inc. stands at 7.94% while the volatility over the past one month is 7.13%.
The market cap for OTLK stock reached $155.22 million, with 121.96 million shares outstanding and 54.45 million shares in the current float. Compared to the average trading volume of 901.09K shares, OTLK reached a trading volume of 24251120 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Outlook Therapeutics Inc. [OTLK]?
Ladenburg Thalmann have made an estimate for Outlook Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 11, 2019. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on May 16, 2019, representing the official price target for Outlook Therapeutics Inc. stock.
The Average True Range (ATR) for Outlook Therapeutics Inc. is set at 0.11 The Price to Book ratio for the last quarter was 46.76, with the Price to Cash per share for the same quarter was set at 0.08.
How has OTLK stock performed recently?
Outlook Therapeutics Inc. [OTLK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.69. With this latest performance, OTLK shares dropped by -28.62% in over the last four-week period, additionally sinking by -32.24% over the last 6 months – not to mention a rise of 3.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OTLK stock in for the last two-week period is set at 28.02, with the RSI for the last a single of trading hit 20.08, and the three-weeks RSI is set at 34.32 for Outlook Therapeutics Inc. [OTLK]. The present Moving Average for the last 50 days of trading for this stock 1.2693, while it was recorded at 1.2230 for the last single week of trading, and 1.0592 for the last 200 days.
Outlook Therapeutics Inc. [OTLK]: Deeper insight into the fundamentals
When it comes to the capital structure of this company, Outlook Therapeutics Inc. [OTLK] has a Total Debt to Total Equity ratio set at 170.78. Additionally, OTLK Total Debt to Total Capital is recorded at 63.07, with Total Debt to Total Assets ending up at 24.46. Long-Term Debt to Equity for the company is recorded at 33.50, with the Long-Term Debt to Total Capital now at 12.37.
Reflecting on the efficiency of the workforce at the company, Outlook Therapeutics Inc. [OTLK] managed to generate an average of -$4,404,937 per employee.Outlook Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.10.
Earnings analysis for Outlook Therapeutics Inc. [OTLK]
With the latest financial reports released by the company, Outlook Therapeutics Inc. posted -0.62/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -148.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OTLK.
Insider trade positions for Outlook Therapeutics Inc. [OTLK]
There are presently around $4 million, or 4.40% of OTLK stock, in the hands of institutional investors. The top three institutional holders of OTLK stocks are: LVW ADVISORS, LLC with ownership of 1,743,633, which is approximately 158.253% of the company’s market cap and around 57.19% of the total institutional ownership; VANGUARD GROUP INC, holding 676,637 shares of the stock with an approximate value of $0.63 million in OTLK stocks shares; and JACOBS LEVY EQUITY MANAGEMENT, INC, currently with $0.28 million in OTLK stock with ownership of nearly New of the company’s market capitalization.
Positions in Outlook Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 24 institutional holders increased their position in Outlook Therapeutics Inc. [NASDAQ:OTLK] by around 2,338,856 shares. Additionally, 8 investors decreased positions by around 111,915 shares, while 4 investors held positions by with 1,455,241 shares. The mentioned changes placed institutional holdings at 3,906,012 shares, according to the latest SEC report filing. OTLK stock had 16 new institutional investments in for a total of 981,089 shares, while 7 institutional investors sold positions of 110,400 shares during the same period.